Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2011  |  Volume : 7  |  Issue : 4  |  Page : 412-415

Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases


1 Department of Surgery, Guro Hospital, Korea University College of Medicine, Seoul, Korea
2 Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Korea
3 Department of Surgery, Ansan Hospital, Korea University College of Medicine, Seoul, Korea
4 Department of Surgery, Anam Hospital, Korea University College of Medicine, Seoul, Korea

Correspondence Address:
Sang Uk Woo
Department of Surgery, Korea University College of Medicine, Guro Hospital, 97 Guro-dong gil, Guro-gu, Seoul
Korea
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.92004

Rights and Permissions

Background: Docetaxel and paclitaxel are likely to have different toxicity profiles, dose reduction and delays despite their similar medical results in breast cancer patients. Aims: This study examined retrospectively the incidence and severity of certain toxicities, dose reduction and delay of two taxanes. Materials and Methods: From January 2009 to June 2010, the incidence and severity of toxicities as well as the dose reduction, dose delay, granulocyte colony stimulating factor (G-CSF) in 54 patients with operable lymph node-positive (tumor stage T1, T2, or T3 and nodal stage N1 or N2) and high risk, node-negative (T2 or T3, N0) breast cancer without a distant metastases who received adjuvant chemotherapy - adriamycin, cyclophosphamide, docetaxel (TAC) and adriamycin, cyclophosphamide, paclitaxel (ACP)- were evaluated. Statistical Analysis Used: Mann-Whitney test and Fisher's exact test. Results and Conclusion: The patients in the ACP group experienced more frequent peripheral neuropathy (P=0.025), nausea (P=0.033) than those in the TAC group. Febrile neutropenia was significant in TAC (P=0.001). Increasing age was associated with an increased risk of anemia (P=0.004), fatigue (P=0.009) and pain (P=0.003), and a decreasing body mass index was associated with an increased risk of febrile neutropenia (P=0.009). Dose reduction and delay occurred due to febrile neutropenia and an increase in aspartate aminotransferase (AST)/alanine aminotransferase (ALT). The dose reduction was only significant in the TAC group (P= 0.001). A taxane-based regimen should be chosen for breast cancer patients based on the pharmacokinetics, dosing schedule, clinical activity and toxicity profile that best meet the patient's therapeutic needs and quality of life.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6609    
    Printed185    
    Emailed2    
    PDF Downloaded479    
    Comments [Add]    
    Cited by others 6    

Recommend this journal